Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 1, 2001, Pages 1-6

  Benigni, Ariela ^a,b   Perico, Norberto ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; LISINOPRIL;

ANIMAL MODEL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; HUMAN; KIDNEY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DISEASE PROGRESSION; ENDOTHELINS; HUMANS; KIDNEY; KIDNEY DISEASES; PROTEINURIA; RECEPTORS, ENDOTHELIN;

EID: 0035133085     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200101000-00001     Document Type: Review

References (66)

1. How far since Ellis?
2. The long-term prognosis of patients with focal segmental glomerulosclerosis
3. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies
4. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
5. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes
6. Does an adequate control of blood pressure protect the kidney in essential hypertension?
7. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
8. Mechanism of angiotensin II induced proteinuria in the rat
9. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?
10. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney
11. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
12. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
13. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat
14. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism
15. Understanding the nature of renal disease progression
16. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes
17. Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease
18. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
19. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group
20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
21. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
22. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
23. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade
24. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism
25. Glomerular protein trafficking and progression of renal disease to terminal uremia
26. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins
27. A new paracrine loop implicated in human tubulo-interstitial fibrosis: Tubular-derived endothelins modulate renal interstitial fibroblast function
28. Chemotaxis of human blood monocytes towards endothelin-1 and the influence of calcium channel blockers
29. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression
30. Passive Heymann nephritis: Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury
31. Increased renal endothelin production in rats with reduced renal mass
32. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy
33. ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats
34. Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat
35. Modulation of glomerular endothelin and endothelin receptor gene expression in aminonucleoside-induced nephrosis
36. Gene expression for endothelin and their receptors in glomeruli of diabetic rats
37. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes
38. B receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis
39. Increased urinary excretion of endothelin-1 and its precursor, big-endothelin-1, in rats chronically treated with cyclosporine
40. Renal endothelin system in polycystic kidney disease
41. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice
42. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension
43. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene
44. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass
45. Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis
46. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy
47. Endothelin antagonists
48. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney
49. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease
50. Changes in urinary excretion of endothelin-1-like immunoreactivity before and after unilateral nephrectomy in humans
51. Increased urinary endothelin-1 like immunoreactivity in NIDDM patients with albuminuria
52. Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: Relation to urinary albumin, blood pressure, and other factors
53. Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome
54. In situ expression of the endothelin gene family in human glomerulonephritis (GN)
55. Gene expression of the endothelin system in renal biopsies of proteinuric patients: Effect of angotensin converting enzyme inhibition
56. Renal immunohistochemical distribution, plasma levels and urinary excretion of endothelin after kidney transplantation
57. Elevated neointimal endothelin-1 in transplantation-associated arteriosclerosis of renal allograft recipients
58. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression
59. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis
60. Effect of a specific endothelin receptor A agonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli
61. A receptor blocker LU 135252 prevents chronic transplant nephropathy in the 'Fisher to Lewis' model
62. Prevention of chronic renal allograft rejection in rats with an oral endothelin a receptor antagonist
63. Contribution of endogenous generation of endothelin-1 to basal vascular tone
64. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
65. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
66. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy